Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides

专利摘要:
The present invention is an effective inhibitor of blood coagulation factor Xa, for example the preparation of acetyl-amidiniophenylalanyl-cyclohexylglyciyl-pyridinioalanineamides and their analogs thereof which can be used for inhibiting thrombosis. It is about a method. Formula I In Formula I, Anion X is a physiologically acceptable anion. The process of the invention is carried out from 2- [2-acetylamino-3- (4-cyanophenyl) -acryloylamino] -2-cyclohexylacetic acid by asymmetric hydrogenation and conversion of cyano groups to amidines. 2- [2-acetylamino-3- (4-amidinophenyl) propionylamino] -2-cyclohexylacetic acid or its salt obtained from 3- (2-amino-2-carbamoylethyl) -1-methyl Coupling with pyridinium salts or salts thereof. The present invention also provides starting materials and intermediates for the process, methods for their preparation and acetyl- (S) -4-amidiniophenylalanyl- (S) -cyclohexylglycosyl- (S) as ditosylate salts. -(1-methyl-3-pyridinio) alanineamide is provided.
公开号:KR20030019306A
申请号:KR1020027009583
申请日:2001-01-18
公开日:2003-03-06
发明作者:브라이폴게르하르트；홀라볼프강；젠드랄라하이너；베크게르하르트
申请人:아벤티스 파마 도이칠란트 게엠베하；
IPC主号:

专利说明:

Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides
[1] The present invention is an effective inhibitor of blood coagulation factor Xa, for example the preparation of acetyl-amidiniophenylalanyl-cyclohexylglyciyl-pyridinioalanineamides and their analogs thereof which can be used for inhibiting thrombosis. It is about a method.
[2]
[3] In Formula I,
[4] Anion X is a physiologically acceptable anion.
[5] The process according to the invention is carried out by asymmetric hydrogenation and the conversion of cyano groups to amidines by 2- [2-acetylamino-3- (4-cyanophenyl) -acryloylamino] -2-cyclohexylacetic acid. 2- [2-acetylamino-3- (4-amidinophenyl) propionylamino] -2-cyclohexylacetic acid or salts thereof obtained from 3- (2-amino-2-carbamoylethyl) -1- Coupling with a methylpyridinium salt or salts thereof. The present invention also provides starting materials and intermediates for the process, methods for their preparation and acetyl- (S) -4-amidiniophenylalanyl- (S) -cyclohexylglycosyl- (S) as ditosylate salts. -(1-methyl-3-pyridinio) alanineamide is provided.
[6] In certain clinical situations, such as, for example, deep vein thrombosis, high-risk myocardial infarction or stable or unstable angina, disturbances and thrombus formation in the blood coagulation system can have fatal consequences. However, in the prevention of thrombosis, excessive or even complete inhibition of the blood coagulation system is undesirable because this can result in life-threatening bleeding. Current coagulation inhibitors such as heparin, aspirin or hirudin do not have optimal character profiles in that they can cause bleeding complications and cannot inhibit vascular occlusion in some of the mentioned clinical situations. Animal experiments show that the specific inhibitor of blood coagulation enzyme factor Xa reliably inhibits thrombus formation, without bleeding, as observed when direct thrombin inhibitors are used. Compounds of formula (I) and their homologues are specific and very potent inhibitors of factor Xa, which are then effective for intravenous, subcutaneous and oral administration.
[7] Compounds of formula (I) and their homologues are described in WO-A 95/29189 and corresponding US Pat. According to WO-A 95/29189, these are 3-pyridylalanine coupled to the resin using a Knorr linker, then coupled to cyclohexylglycine, the pyridine nitrogen atom is quaternized, Dipeptides are coupled by acetyl-4-amidinophenylalanine prepared from 4-cyanophenylalanine and prepared by solid phase synthesis using protective group techniques to chromatographically purify the product partitioned from the resin. Such solid phase processes are inadequate for producing the amount of kilograms required for development work such as toxicological and clinical studies, and large scale synthesis cannot be expected at all.
[8] Pharmaceutically active compounds are acceptable as developmental products, where the process for their preparation can then be carried out on a predetermined scale with a suitable purity (in the case of compounds with asymmetric centers, the purity of which also includes stereochemical purity in particular). Can only be used in patients. Compounds of formula (I) contain peptidic diions that carry a positive charge on the amidinium group and the N-methylpyridinium group. Trifluoroacetate salts in compounds of formula (I) with different anions X ^- for example acetate, chloride, fumarate, benzoate, tartarate, maleate, trifluoroacetate, tosylate, sulfate or pamoate Only (compound of formula (I) wherein X ⁻ is CF ₃ CO ₂ ⁻ ) has been found to be crystalline. However, the thermal stability of the trifluoroacetate salt is insufficient, its life is unsatisfactory, and from a physiological point of view, the salt is less desirable for long-term use. X-ray powder diagrams of all other salts of compounds of formula (I) were found to be severely amorphous. The amorphous nature of the salts is a significant problem for preparing compounds of formula (I) on a relatively large scale, because these properties make recrystallization impossible, and fractional precipitation is the only purification method that can be implemented for large scale use. However, since the purification efficiency of precipitation is of course much lower than the crystallization efficiency, coarse compounds of formula (I) with suitable anions X, even in reactions that proceed as smoothly as possible, result in fractional precipitation of products of clinically acceptable purity. It is necessary to be able to obtain by. However, the method of preparation should of course be acceptable for factors such as yield, number of steps or effectiveness and cost of starting material.
[9] Processes for the preparation of compounds of formula (I) which are not carried out in the solid phase are described in WO-A 97/22712. In this method, the three amino acid units contained in the compound of formula (I) are combined in the same order as in the method of WO-A 96/29189. (S) -3-pyridylalanine protected by a tert-butoxycarbonyl group (Boc) in the amino group is initially converted to an amide and then (S) -N-Boc-cyclohexyl after removal of the protecting group Coupling with glycine, protecting group removed, dipeptide coupled with acetyl- (S) -4-cyanophenylalanine, and the cyano group in the resulting tripeptide combined with hydrogen sulfide, methyl iodide and ammonia The reaction is converted to amidine and the pyridine nitrogen atom is quaternized. The product is separated in the form of the trifluoroacetic acid salt by evaporation of the reaction solution obtained in the final step, dissolution of the residue, addition of trifluoroacetic acid, filtration and freeze drying. However, the purity of the product obtained by the present invention, including stereochemical purity, does not meet the requirements and involves a large amount of loss and requires complex chromatographic purification that is unacceptable when the process is carried out on a large scale. It turned out. In order to avoid possible obstacles from the physiological point of view for the trifluoroacetate anion, it is also necessary to convert the product to different salts using ion exchange chromatography. In addition, the process has significant technical drawbacks, for example, using three solvents, such as diethyl ether or hexane, or at low temperatures and containing expensive starting materials [three enantio groups as base components in the compounds of formula (I). Mechanically pure synthetic α-amino acids (S) -3-pyridylalanine, (S) -cyclohexylglycine and (S) -4-amidinophenylalanine (or (S) -4-cyanophenylalanine; amidino groups Small amounts are commercially available, but these compounds are very expensive. Thus, there is still a need for a smooth method of operation for large-scale preparation of compounds of formula (I) with suitable anions X.
[10] It is an object of the present invention to convert a compound of formula (II) to a compound of formula (III) or a salt thereof with acid HX by catalytic hydrogenation and conversion of a cyano group to an amidino group, followed by a compound of formula (III) or a salt thereof By a process for the preparation of compounds of formula (I) according to the invention, comprising the reaction of compounds of formula (IV) or salts with acids HX thereof to obtain compounds of formula (I) wherein anion (X) is a physiologically acceptable anion.
[11]
[12] In known methods, the molecules of formula (I) are prepared by coupling the C-terminal dipeptides of pyridylalanine and cyclohexylglycine with the N-terminal amino acid amidinophenylalanine (or cyanophenylalanine), while the process according to the invention Molecules are synthesized by coupling the N-terminal dipeptides of amidinophenylalanine and cyclohexylglycine with the C-terminal amino acid pyridylalanine. In addition, in the process according to the invention, the structural unit CH-CO-NH-CH-CO having two chiral centers which are sensitive to epimerization among the dipeptides used for such coupling, as in known methods, has two chirals. It is not formed in the coupling reaction of α-amino acids but by asymmetric hydrogenation. In the process according to the invention, peptide coupling uses pure, quantitative and inexpensive reagents. The degree of epimerization is very low. Compounds of formula (I) are obtained in high yield and in high chemical and stereochemical purity by fractional precipitation. Chromatographic purification or expensive complex techniques such as lyophilization are not necessary to obtain the desired purity.
[13] The present invention is also analogous to the process described above, using stereo arrays of starting materials, stereoisomers of the compounds of formula (I), for example chiral centers of amidinophenylalanine units, have (R) configuration and / or cyclohexylglycine Provided are methods for preparing compounds wherein the chiral center of the unit has an (R) configuration and / or the chiral center of the pyridylalanine unit has an (R) configuration or a compound present on the one or more chiral centers as an (RS) mixture. do. The present invention is also analogous to the process described above, and using suitable starting materials, the homologues (and stereoisomers thereof) of the compounds of formula (I), for example amidinophenylalanine units, instead of the methyl group in the acetylamino group (C ₁ − Containing C ₄ ) -alkyl groups and / or (C ₁ -C ₄ ) -alkyl groups instead of methyl groups in the quaternary pyridine nitrogen atom, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, Provided are methods for preparing compounds containing (C ₁ -C ₄ ) -alkyl groups, such as isobutyl and tertiary butyl.
[14] The physiologically acceptable anions X in the compounds of the formulas (I) and (IV) and in the acid HX may be, for example, chloride, bromide, iodide, methanesulfonate, toluene-4-sulfonate, acetate, benzoate and the like. In the case of polyvalent anions, for example sulfate, X is the anion equivalent. X has no problem from a physiological point of view even when the compound of formula (I) is used at a relatively high dosage for a relatively long time, and / or is desirable for a compound of formula (I) in terms of pharmaceutical processing and pharmacological action, such as in water Desirable properties for the compounds of formulas (I) and (IV), for example in terms of imparting suitable solubility to and / or technically carrying out the process according to the invention, for example simplicity of the process, suitable solubility in the solvent used, precipitation and / or Or an anion imparting ease of filtration or the like. And or iodide, in a preferred embodiment of the invention, X is toluene-4-sulfonate (= 4-methyl benzene sulfonate _{= 4-CH 3 -C 6 H} 4 -SO 3 - - = tosylate = TosO) In a particularly preferred embodiment, X is toluene-4-sulfonate. Thus, in this particularly preferred embodiment, the invention converts a compound of formula II to a compound of formula III or toluene-4-sulfonic acid salt thereof by catalytic hydrogenation and conversion of cyano groups to amidino groups, A compound of formula I in the form of the ditosylate salt, i.e., comprising reacting a compound of formula III or a toluene sulfonic acid salt thereof with a compound of formula IVa or a toluene-4-sulfonic acid salt thereof to obtain a compound of formula A method for preparing a compound of formula (la) is disclosed.
[15]
[16]
[17] From a physiological point of view, there is no problem with tosylate anions contained in the compounds of formula (Ia), and the compounds of formula (Ia) are identified by their particularly good properties, especially when carrying out the process according to the invention. Compounds of formula (Ia) are easy to precipitate and filter, especially obtained in high yield and high purity. The present invention also encompasses the compounds of formula (Ia) and their solvates, such as adducts with water or alcohols, as inhibitors of factor Xa or for the treatment and prevention of thromboembolism, for example thrombosis, myocardial infarction or angina pectoris. Use of a compound of formula (Ia) for treatment, and a pharmaceutical formulation comprising a drug for such a medical use and an effective amount of the compound of formula (Ia) and a pharmaceutically acceptable carrier, ie, one or more pharmaceutically acceptable excipients and / or additives Provided is the use of a compound of formula la for the preparation of (or pharmaceutical composition). A more detailed description of the use of the compounds of formula (I) comprising the compounds of formula (Ia) and of the pharmaceutical preparations comprising them is given in WO-A 95/29189 and US Pat. It is.
[18] In addition to the above-described methods for preparing compounds of Formula (I) and preparing compounds of Formula (Ia) from compounds of Formulas (II) and (IV), or salts thereof, the present invention relates to compounds of Formula (III) or toluene-4-sulfonic acid salts thereof of Formula (IVa). A process for the preparation of a compound of formula (Ia) comprising reacting with a compound or a toluene-4-sulfonic acid salt thereof to give a compound of formula (Ia). For this method characterized by the fact that formula (I) provides the compounds in particular ditosylate forms with surprisingly good yields and purity and can be carried out in a particularly smooth and simple manner, the compounds of formulas (III) and (IV) All the descriptions given above and below for the reaction of the salts of ie the peptide coupling step with respect to the above process apply accordingly.
[19]
[20] The compounds of formula (I) may also be represented by compounds of formula (V), which are formally acid addition salts with the acid HX and the monocationic amidino substituted pyridinium salts contained in the compounds of formula (V) in the compounds of Free amidino group instead of protonated, positively charged amidinogroup -C (= NH ₂ ⁺ ) -NH ₂ (= with carbamimidoyl group = amino-imino-methyl group -C (= NH) -NH ₂ ] It can be considered as.
[21]
[22] Correspondingly, the compounds also have acid additions with dicationic pyridinium salts or acids HX in different ways, for example containing positively charged amidino groups as substituents and two negatively charged anions X as counterions. It may also be termed a monocationic pyridinium salt containing free amidino groups as salts and substituents and negatively charged anions X as counterions. Depending on the respective situation, other nomenclature methods, for example, positively charged amidinium groups (= amidinio groups) or free amidine groups and positively charged pyridinium groups (= pyridinio groups) are substituted Names derived from peptide nomenclature to be regarded as may also be suitable. The compound of formula (Ia) is, for example, 3-{(S) -2-[(S) -2-((S) -2-acetylamino-3- (4-amidiniophenyl) propionylamino)- 2-cyclohexylacetylamino] -2-carbamoylethyl} -1-methylpyridinium ditosylate or 3-{(S) -2-[(S) -2-((S) -2-acetylamino- 3- (4-amidinophenyl) propionylamino) -2-cyclohexylacetylamino] -2-carbamoylethyl} -1-methylpyridinium tosylate toluene-4-sulfonic acid salt, or N-acetyl-4 -(Amino-imino-methyl) -L-phenylalanyl-L-2-cyclohexylglycyl-3- (1-methylpyridinium-3-yl) -L-alanineamide tosylate toluene-4-sul It may be referred to as a phonic acid salt.
[23] When carrying out the process according to the invention, the compound of formula (II) initially undergoes hydrogenation of the compound of formula (II) in a stereoselective manner to obtain a compound of formula (VI), and then converts the cyano group to amidine or initially The no group can be converted to amidine and then converted to the compound of formula III by stereoselective hydrogenation.
[24]
[25] Preferably, the hydrogenation reaction to give the compound of formula VI is carried out first, and then the cyano group is converted to amidine.
[26] Stereoregulated hydrogenation of C = C double bonds in the dihydrodipeptides of Formula II can be carried out using selective heterogeneous catalysts or chiral transition metal complexes. It is preferably carried out using chiral metal complexes of rhodium (I) or ruthenium (II), particularly preferably rhodium (I). The transition metal catalyst may be cationic or neutral, which may be used in isolated form or may be a chiral ligand and a procatalyst such as a rhodium salt such as [Rh (COD) Cl] ₂ or [Rh (COD) ₂ ] ⁺ Y ⁻ , wherein COD is 1,5-cyclooctadiene and Y is, for example, tetrafluoroborate, in situ in the hydrogenation medium. The hydrogenation catalyst can be present in homogeneously dissolved form in the hydrogenation medium, or it can be heterogenized by attaching to a solid support, which can be easily removed by filtration after the hydrogenation is terminated and reused in the next hydrogenation batch. Can be. As chiral ligands for transition metal complexes, many different compounds are suitable. An overview of such chiral ligands can be found, for example, in I. Ojima, Catalytic Asymmetric Synthesis, pages 445-447, VCH, New York 1993. In a preferred embodiment of the invention, rhodium (I) complexes having chiral phosphines as ligands are used for the asymmetric hydrogenation of compounds of formula (II) to obtain compounds of formula (VI). Rh (I)-(+)-BPPM catalyst, ie (+)-(2R, 4R) -1-tertiary butyloxycarbonyl-4-diphenylphosphino-2- (diphenylphosphinomethyl as chiral ligand Particular preference is given to rhodium (I) catalysts comprising pyrrolidine (molar ratio of rhodium: ligand = 1: 1). The catalyst is preferably prepared in situ from the rhodium salt and the ligand.
[27] Suitable solvents for the stereoselective hydrogenation of compounds of formula II to obtain compounds of formula VI are, for example, ethers, especially water miscible ethers or lower alcohols such as methanol, ethanol or isopropanol. The hydrogenation reaction is particularly preferably carried out in methanol. The hydrogenation reaction is preferably carried out at a temperature of about 20 to about 60 ° C, particularly preferably about 30 to about 50 ° C, for example about 40 ° C. The hydrogen pressure set depends on the device used; The hydrogen pressure is preferably set to about 1 to about 20 bar, particularly preferably about 5 to about 15 bar, for example about 10 bar. In order to increase the hydrogenation efficiency, the reaction is carried out with a substantially homogenous and very homogeneous mixing of oxygen. The hydrogenated product can be separated in a simple manner by adding water and filtering off or centrifuging the resulting precipitate. The asymmetric hydrogenation reaction proceeds with very high stereoselectivity and yield, and the (S, S) -isomer 98.4% d.e. And a diastereomeric excess of 99.5% d.e. in the product isolated at 97% separation yield. In addition, these excellent results are obtained at very high substrate / catalyst ratios of about 2000: 1 to about 5000: 1.
[28] The invention also relates to the compounds of formula VI itself, namely (S) -2-[(S) -2-acetylamino-3- (4-cyanophenyl) propionylamino] -2-cyclohexylacetic acid and salts thereof, For example, alkali metal or alkaline earth metal salts, such as sodium salts or potassium salts, the preparation methods and intermediates thereof, as described above, in particular their use as intermediates for pharmaceutically active substances.
[29] The cyano group in the compound of formula VI has a number of disadvantages when performed by various methods known per se to the person skilled in the art, for example on a large scale, for example using hydrogen sulfide. It can be converted to amidine by the method described in / 22712. The conversion reaction is preferably carried out initially by adding hydroxylamine to the cyano group in the compound of formula VI to form the N-hydroxyamidine intermediate of formula VII. The compound of formula VII is then converted to amidine of formula III in a simple manner by hydrogenolysis, ie by reaction with hydrogen in the presence of a hydrogenation catalyst. The principle of this reaction sequence is described, for example, in H. Jendralla et al., Tetrahedron 51 (1995) 12047.
[30] The required hydroxylamine is advantageously prepared in situ from hydroxylammonium salts such as hydroxylammonium chloride or hydroxylammonium sulfate and bases such as basic sodium or potassium compounds or tertiary amines. The base used for the reaction of the compound of formula VI with the hydroxylammonium salt is preferably sodium hydrogen carbonate. The hydroxylamine or hydroxylammonium salts are preferably used in excess, for example in an amount of about 1 to about 2 mol per mol of the compound of formula VI. Suitable solvents for reaction with hydroxylamine or hydroxylammonium salts are, for example, lower alcohols. Particularly preferred solvent is methanol. The compound of formula VII is preferably prepared at a temperature of about 20 to about 65 ° C., particularly preferably at a temperature of about 40 to about 60 ° C. If hydroxylammonium salts are used, the added base also converts the carboxylic acid functionality in the compound of formula VI or the carboxylic acid functionality in the compound of formula VII to the corresponding salt. For the purpose of intermediate separation of the N-hydroxyamidines of formula VII, the compounds are in the form of salts in the carboxylic acid functional groups, i.e. if the base used is a sodium compound, the reaction mixture is concentrated in a relatively nonpolar solvent and / or The separation can be carried out in an advantageous manner in the form of the sodium salts of carboxylic acids which can be precipitated by mixing and separated by filtration or centrifugation.
[31] Hydrolysis of the compound of formula VII or a salt thereof to obtain a compound of formula III can be carried out under conditions customary for catalytic hydrogenation reactions, for example in the presence of conventional noble metal catalysts such as palladium on carbon. . The reaction conditions depend on the device used. The hydrogen pressure may, for example, range from about 1 to about 30 bar, in particular from about 5 to about 25 bar, and the reaction temperature may be from about 20 to about 70 ° C, in particular from about 40 to about 60 ° C. Hydrolysis is preferably carried out in acidic medium. Preferred solvents for hydrogenolysis are polar solvents, for example lower alcohols or acetic acid, especially when N-hydroxyamidine is used in the form of salts. Particularly preferred solvent is acetic acid. The resulting amidine compound of formula III is not present on its own or in the form of an acid addition salt (the amidine compound of formula III itself is not present in the form having the free amidino group and the carboxylic acid group represented by the compound of formula III, Separate from this carboxylate anion and present in the tautomeric form of formula IIIa, i.e. in the form of betaine or zwitterion, wherein the amidine unit is protonated in the amidinium cation).
[32]
[33]
[34] The compound of formula III is obtained as an acid addition salt, even in the presence of an acid which may be present even during hydrolysis, for example when the solvent used is acetic acid, or in the presence of an acid which can be added during workup. Thus, the acid of formula HX is used to form salts of formula VIII wherein anion X is preferably a physiologically acceptable anion such as iodide or tosylate. Compounds of formula VIII are the aforementioned salts of acids HX and compounds of formula III. When the compound of formula III is separated in acid addition salt form, the acid HX is preferably selected to contain the same anion as the compound of formula I in which the compound of formula VIII is to be prepared. Thus, if the ditosylate salt of formula (Ia) is prepared and the compound of formula (III) is isolated as a salt, the amidinium tosyl of formula (VIII) wherein X is TosO ^- by adding toluene-4-sulfonic acid, for example, during workup. It is desirable to prepare the rate. As described above, for the peptide coupling reaction with the compound of formula IV, the compound of formula III itself, i.e., betaine (or zwitterion) of formula IIIa, or an amidinium salt of formula VIII (= HX with Salts with compounds of formula III) can be used, in both cases providing similar purity and yield. The compound of formula III is preferably isolated as betaine (or zwitterion) of formula IIIa and used by itself in a peptide coupling reaction. If the hydrogenolysis is carried out in an acetic acid salt of the compound of formula III formed in the initial (= X ^- a compound of the acetate of the formula VIII) it can be converted to betaine by recrystallization from water.
[35] The present invention also relates to the compounds of formula III and salts thereof and to betaine (zwitterions) which are the compounds of formulas IIIa and VIII themselves and to their salt forms (S) -2-[(S) -2-acetylamino-3 -(4-amidinophenyl) propionylamino] -2-cyclohexylacetic acid, the above-mentioned preparation method for preparing them, and their use as intermediates, especially intermediates for pharmaceutically active compounds.
[36] Peptide coupling reactions of the amidine of formula III (in the form of a salt or preferably the betaine form of formula IIIa) with the pyridinioalanineamide of formula (IV) or salts thereof to obtain a compound of formula (I) are known to those skilled in the art. It may be carried out by a known conventional coupling method.
[37] The pyridinioalaninamide is preferably used in the form of a salt with acid HX, ie in the form of the dicationic salt of formula IX, wherein anion X is preferably a physiologically acceptable anion.
[38]
[39] When anion X in a compound of formula IV or a compound of formula IX and a compound of formula III are used in the form of a salt of formula VIII, the anion in the compound of formula VIII is preferably an anion of the compound of formula I to be prepared, i.e. When preparing the compound of, tosylate anion. When neither the compound of formula III nor the compound of formula IV is used in salt form with acid HX for the peptide coupling reaction, the anion required to prepare the compound of formula I in addition to the equivalent of anion X introduced by the compound of formula IV A second equivalent of X can be added in the form of an equivalent of acid HX or salt with acid HX during workup of the peptide coupling reaction mixture.
[40] Examples of peptide coupling agents suitable for carboxylic acid or carboxylate functional activation in a compound of formula III (or a compound of formula IIIa or VIII), which may be mentioned, include carbodiimides such as dicyclohexylcarbodiimide (DCC). ) Or diisopropylcarbodiimide (DIC), or uronium salts, for example O-[(cyano-ethoxycarbonyl-methylene) amino] -N, N, N ', N'-tetramethyluro Nium tetrafluoroborate (TOTU) or O- (7-azabenzotriazol-1-yl) -N, N, N ', N'-tetramethyluronium hexafluorophosphate (HATU). The carbodiimide is preferably a hydroxybenzotriazine or a hydroxybenzotriazole reagent, for example 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (= 3-hydroxy-1,2,3-benzotriazine-4 (3H) -one = HOObt) or 1-hydroxy-1H-benzotriazole (HObt). Since the degree of epimerization is minimal at chiral carbon atoms, especially at the α-position to the carbonyl group in the compound of formula III, activators and reaction conditions that allow only some diastereomeric impurities to be formed, in some cases, desirable. Particularly preferred activators in this respect are HATU, DCC / HOObt and DCC / HObt. In particular, using HATU or DCC / HOObt, the coupling reaction yields a product containing only 0.7-1.5% diastereomer in the crude product. Due to its fairly low price, DCC / HOObt is particularly preferred. Due to the stability, HOObt can preferably be used on a support, for example on Dicalite ^R.
[41] The coupling reaction is preferably carried out in a polar solvent (or solvent mixture). Suitable solvents are protic solvents, for example lower alcohols (e.g. methanol, ethanol or isopropanol), of which isopropanol is preferred, which has a lower risk of conversion of C-terminal amide groups to esters than methanol or ethanol. Because. Particularly preferably, the coupling reaction is carried out in an aprotic polar solvent in which the coupling reaction proceeds particularly rapidly and clearly, for example amides [eg N, N-dimethylformamide (DMF) or N-methyl-2- Pyrrolidone (NMP)] or dimethyl sulfoxide (DMSO). However, it is also possible to use solvents such as, for example, ethyl acetate, tetrahydrofuran (THF) or methylene chloride, in particular also mixtures with other solvents. Very particularly preferably, the coupling reaction is carried out in DMF or NMP, both giving good coupling results and separation yields of 85 to 95% (after two product precipitations) of the compounds of formula (I). Especially preferably, the coupling reaction is carried out in DMF because it can be more easily removed from the product. The coupling reaction is preferably carried out at a temperature of about 0 to about 30 ° C., particularly preferably about 0 to 25 ° C., for example by initially stirring the reaction mixture at about 10 ° C. and then warming it to room temperature. do. In a preferred embodiment of the coupling step, when the compound of formula III is reacted with the dicationic salt of formula IX in the zwitterion form of formula IIIa, the preferred pH (about 3.3 to 4.2 when X in the compound of formula IX is tosylate) ) Is generally maintained without the need for adding additional base during the overall coupling process. Optionally, the pH can be appropriately adjusted by adding a base, for example tertiary amine. When both compounds of formula III and compounds of formula IV are used in the form of salts with acid HX in the coupling reaction, the peptide coupling reaction may comprise at least one equivalent of a base such as a tertiary amine such as triethylamine or Preferably, N-ethyldiisopropylamine needs to be added.
[42] In a preferred embodiment of the coupling step, when the activator used is an N-hydroxybenzotriazine or N-hydroxybenzotriazole reagent, for example carbodiimide together with HOObt, this reagent is Since it is regenerated during the reaction of a compound of formula IV with an active ester formed immediately from a compound of formula III and an N-hydroxy reagent, it may be present in a stoichiometric amount or below in a catalytic amount. For example, when the coupling reaction is carried out using DCC / HOObt, the HOObt is preferably in an amount of about 0.15 to about 1 mol per mol of the compound of formula III, particularly preferably from about 0.2 to 1 mol of compound of formula III It is used in an amount of about 0.3 mol, for example about 0.25 mol. Carbodiimide is preferably used in slightly excess. When the coupling reaction is carried out using DCC / HOObt, for example, preferably in an amount of from about 1.1 to about 1.4 mol per mol of the compound of formula III, particularly preferably from about 1.2 to about 1.3 mol of compound of formula III mol, for example about 1.25 mol. The order of adding the reactants is variable. Initially the compounds of formulas III and IV or salts thereof, certain bases and N-hydroxy reagents which can be added are charged and carbodiimide, for example DMF for several hours, for example from about 5 to about 10 hours. Or metered in in the form of a solution in a solvent such as NMP. In this method, the coupling reaction at a reaction temperature of about 10 ° C. followed by stirring at room temperature is generally completed quickly, in fact occurs quantitatively, and provide a high purity product.
[43] For workup, the reaction mixture is advantageously initially filtered and then the product is precipitated by addition of a suitable organic solvent. If the coupling reaction is carried out in DMF or NMP, the precipitation is preferably carried out dropwise using an excess of lower ketones, for example acetone or methyl ethyl ketone, particularly preferably by dropping the DMF solution or NMP solution or by pump It is carried out by dropwise addition of excess acetone or methyl ethyl ketone. The precipitated product is separated by filtration or centrifugation, washed and, if desired for increased purity, twice or three times in a similar manner (eg, the product is dissolved in DMF and the solution is acetone or methyl Precipitate by pumping into ethyl ketone). In this way, most of the by-products remain in solution and after two precipitations, for example, the compound of formula la (ditosylate) has a yield of about 91% and a purity of about 97% (+ about 2.4% diastereo) Mer).
[44] The starting materials of the formulas (II) and (IV) or salts thereof used in the process according to the invention described above can be prepared, for example, by the following process. In a preferred form of the process according to the invention described above, the starting materials of the general formula (II) and / or the starting materials of the general formula (IV) or salts thereof are prepared by the following process, or by some of the following processes.
[45]
[46] Compounds of formula II can be obtained by reacting azlactone of formula XI with (S) -cyclohexylglycine (compound of formula XII). The azlactones of formula (XI), which are essentially present as Z isomers, are prepared, for example, under standard conditions for the synthesis of Erlenmeyer azlactone from 4-formylbenzonittyl (compound of formula X) and N-acetylglycine. It is formed by heating sodium acetate and acetic anhydride in a solvent, preferably in acetone under reflux. The reaction of the compound of formula (XI) with the compound of formula (XII) to obtain the dehydrodipeptide of formula (II) is preferably in an alkaline solution at a temperature of about 30 to about 50 ° C., for example about 40 ° C., for example 1 By adding an equivalent (based on cyclhexylglycine) base, such as sodium or potassium hydroxide, to water and a water miscible organic solvent, such as a ketone (eg acetone) or ether, particularly preferably a mixture of acetone and water Is performed. To separate the product, the reaction product is acidified to pH about 2.3 with hydrochloric acid, diluted with water, and the precipitate is filtered off or centrifuged off. In this way, the resulting compound of formula (II) is mainly present as the Z isomer, and the% abundance of the E isomer is less than 2%. The present invention also provides the compounds of the formulas (II) and (XI) and the salts of the compounds of the formula (II) themselves, in particular the Z form, the above-mentioned preparation methods for preparing them, and their use as intermediates, in particular intermediates for pharmaceutically active compounds. Salts of the compounds of formula (II) which may be mentioned are, for example, alkali metal and alkaline earth metal salts, for example sodium salts or potassium salts.
[47] The required optically pure (S) -cyclohexylglycine (compound of formula XII) is advantageously prepared by one of the following three routes. In one route, the starting materials used are noble metal catalysts in hydrochloric acid by hydrogenation of aromatic rings under standard conditions, for example at hydrogen pressures of about 10 to about 30 bar at about 80 to about 120 ° C., for example about 100 ° C., Racemic phenylglycine (compound of formula XIII) which is converted, for example, to racemate cyclohexylglycine (compound of formula XIV) by hydrogenation in the presence of rhodium on carbon. The racemate cyclohexylglycine is then acetylated using acetic anhydride in the presence of a base in water, eg sodium hydroxide, under standard conditions in the amino group, for example at a pH of at least 11 at a temperature of about 0 to about 30 ° C. Make up. The racemate N-acetyl-cyclohexylglycine (compound of Formula XV) is then subjected to enzymatic racemate digestion using acylase (L-specific aminoacylase, EC3.5.1.14), which results in a very large amount of ( R) Optically pure (S) -cyclohexylglycine (compound of formula XII) and N-acetylcyclohexylglycine containing the colon (compound of formula XVI) are obtained. See K. Drauz et al., Enzyme. Catalysis in Organic Synthesis, VCH, Weinheim, 1995; M.A. Verkhovskaya et al., Russ. Chem. Rev. 60 (1991) 1163; H. K. Chenault et al., J. Am. Chem. Soc. 111 (1989) 6354. Selective enzyme deacetylation of (S) -N-acetyl-cyclohexylglycine in the (RS) mixture is, for example, in the presence of cobalt (II) chloride in water at a pH of about 7.8 at a temperature of about 38 to 40 ° C. Asilase "Amano" can be performed using 30 000. Cyclohexylglycine that precipitates is substantially enantiomerically pure (S) isomer. (R) -N-acetylcyclohexylglycine remaining in the filtrate is subjected to enzymatic deacetylation again after racemization, for example by heating acetic acid and acetic anhydride at about 115 ° C., and eventually substantially all racemic Sieve N-acetylcyclohexylglycine is converted to optically pure (S) -cyclohexylglycine.
[48]
[49] A second possible method for preparing (S) -cyclohexylglycine is the racemate N-acetylcyclohexylglycine (compound of formula XV) by palladium catalyzed amidocarbonylation from cyclohexanecarbaldehyde, carbon monoxide and acetamide Is prepared in a one step process, and then the obtained racemate is digested with acylase. See M. Beller et al., Chem. Eur. J. 4 (1998) 935.
[50] In a third process for preparing (S) -cyclohexylglycine (compound of formula XII), the phenyl group in enantiomerically pure (S) -phenylglycine (compound of formula XVII) is a cyclohexyl group under nonracemicization conditions. Hydrogenated. Suitable catalysts are also noble metal catalysts, for example rhodium on carbon. The hydrogenation reaction is preferably carried out in an acidic medium such as carboxylic acid (such as glacial acetic acid), particularly preferably in a strong acid such as 2N hydrochloric acid or sulfuric acid. Among the strong acids described above, the hydrogenation reaction proceeds rapidly without significant racemization at temperatures of about 60 to about 80 ° C. and, for example, hydrogen pressures of about 20 bar. The resulting product has a similar quality to the product obtained from racemate phenylglycine from the process described above. Starting material (S) -phenylglycine is more expensive than starting material (RS) -phenylglycine, but because of their low production cost, the method of using (S) -phenylglycine as starting material is more advantageous.
[51] Enantiomerically pure starting materials of formula (IV) or salts of formula (IX) are advantageously combined with N-acetylglycine in acetone under conditions similar to those described above for converting compounds of formula (X) to compounds of formula (XI). Prepared starting from pyridine-3-carbaldehyde (compound of formula XVIII) which can be converted to an azlactone of formula XIX by heating acetic anhydride. Azelactone of formula (XIX) is solvolyzed with water to give N-acetyldehydropyridylalanine, ie a carboxylic acid, or a lower alcohol such as (C ₁ -C ₃ ) -alkanol, for example methanol or ethanol. Can be used to obtain carboxylic esters, preferably methanol to give methyl esters (compare compounds of formula XX). As the subsequent asymmetric hydrogenation reaction is carried out particularly advantageously in alcohol under acidic conditions, almost or all of the carboxylic acid functional groups are converted to esters and solubilization by alcohols of the azlactones of formula XIX is more than with water. Proceeding smoothly, the compound of formula XIX is preferably solvolyzed with a lower alcohol, particularly preferably methanol. The dialcoholization is preferably carried out at a temperature of about 50 to about 65 ° C. in the presence of a weak base such as a tertiary amine such as triethylamine. The methyl esters are preferably separated in the form of acid addition salts using strong acids, ie in the form of compounds of formula (XX) wherein the anion Y is an anion of the strong acid, for example tetrafluoroborate or tosylate. Particularly preferably, the methanolysis product of azlactone of formula XIX is precipitated as a tetrafluoroborate salt by addition of an aqueous tetrafluoroborate solution, for example a pH of about 1.5 to about 2, for example up to about 1.9. The product is filtered off or centrifuged after the precipitation is terminated by adding an ether such as a nonpolar solvent, for example methyl tertiary butyl ether. Compounds of formula (XX) wherein Y is BF ₄ are obtained in high yield (90%) and in very high purity (greater than 99.5%).
[52]
[53] The next step is an asymmetric catalytic hydrogenation of the dehydropyridylalanine derivative of formula XX to obtain an optically active amino acid derivative of formula XXI. As mentioned above, in order to obtain high yields and short reaction times, the hydrogenation reaction is preferably under acidic conditions, for example in acetic acid, particularly preferably in a stoichiometric amount or more, for example 1 to 2 It is carried out in the presence of a strong acid, such as toluene-4-sulfonic acid or boron tetrafluoride, which is used in fold molar amounts to completely convert the pyridine groups to pyridinium salts. For the hydrogenation reaction, preference is given to using pyridinium salts of the formula (XX) and, if appropriate, further acids. Particularly preferably, the hydrogenation of the pyridinium salts of formula XX, in particular the salts with Y of BF ₄ , is carried out in the lower alcohols, in particular methanol, in the presence of about 15 mol% of the strong acid. Preferred acids present in carrying out the hydrogenation of the salts of formula (XX) are boron tetrafluoride and toluene-4-sulfonic acid, in particular tetrafluoroboric acid which can be used in the form of aqueous solutions.
[54] With respect to the catalyst for the asymmetric hydrogenation reaction of the compound of formula (XX) to the compound of formula (XXI), the description given above for the catalyst for the hydrogenation reaction of the compound of formula (II) to the compound of formula (VI) applies correspondingly. Accordingly, the stereoregulated hydrogenation of C = C double bonds in compounds of formula (XX) can also be carried out using selective heterogeneous catalysts or using chiral transition metal complexes. Preference is given to using chiral metal complexes of rhodium (I) or ruthenium (II), in particular rhodium (I). The transition metal catalyst may be used in isolated form or may be formed in situ in a hydrogenation medium from chiral ligands and procatalysts such as rhodium salts such as [Rh (COD) Cl] ₂ . The catalyst is preferably prepared in situ. As chiral ligands for transition metal complexes, many different compounds are also suitable. In a preferred embodiment of the invention, the catalyst used for asymmetric hydrogenation of a compound of formula XX to a compound of formula XXI is a rhodium (I) complex having a chiral phosphine as ligand, particularly preferably Rh (I)-( +)-Phenyl-CAPP catalyst, ie containing (+)-(2R, 4R) -1-phenylaminocarbonyl-4-diphenylphosphino-2- (diphenylphosphinomethyl) pyrrolidine as chiral ligand Halodium (I) catalyst (molar ratio of rhodium: ligand = 1: 1). However, suitable for use as ligands in the catalyst complex are also described, for example, as described above for example (+)-BPPM or aminophosphinephosphinite (+)-PPP [= (+)-prophrafos. Dobler et al., Tetrahedron: Asymmetry 7 (1996) 117). Additional ligands for suitable catalytically active transition metal complexes are listed, for example, in I. Ojima, Catalytic Asymmetric Synthesis, pages 445-447, VCH, New York 1993.
[55] The hydrogenation reaction of the compound of formula XX is preferably carried out at a temperature of about 20 to about 60 ° C, particularly preferably about 30 to about 50 ° C, for example about 40 ° C. In addition, the hydrogen pressure used depends on the apparatus used; A hydrogen pressure of about 0.2 to about 20 bar, particularly preferably about 0.2 to about 10 bar, particularly preferably about 0.5 to about 1 bar, for example about 0.8 bar, is preferred. In particular, when the Rh (I) -phenyl-CAPP catalyst is used, the hydrogenation reaction is preferably carried out at relatively low hydrogen pressures in order to increase enantioselectivity. In the present invention also as described above for the hydrogenation reaction of the compound of formula II, the reaction is carried out with a very homogeneous mixing, substantially excluding oxygen, in order to increase the hydrogenation efficiency. The hydrogenation products of the formula XXI, in particular in the case of tetrafluoroborate, are preferably separated by crystallization from alcohols, for example isopropanol. The isolated yield is about 86 to about 95% and the enantiomeric purity is about 70 to about 95% e.e. of the (S) isomer, depending on the selection conditions. For the hydrogenation of a compound of formula XX to a compound of formula XXI, very high substrate / catalyst ratios of about 5,000: 1 to about 10,000: 1, for example about 8,000: 1, can be used.
[56] In the next step, the methyl ester group in the compound of formula XXI is hydrolyzed to obtain a carboxylic acid group, the acetyl group is removed from the amino group, and the amino group is protected in a suitable manner so as not to cause side reactions during formation of the carboxamide functional group. . Removal of the acetyl group and hydrolysis of the methyl ester to the free carboxylic acid may be carried out using an acid, for example an aqueous acid such as 1N hydrochloric acid or 4N hydrochloric acid, for example from about 60 to about 85 ° C or from about 85 to about 90 ° C. It can be done simultaneously by treating at temperature. The free amino group can then advantageously be immediately converted to an acylamino group and then easily deprotected, for example with a benzyloxycarbonylamino group, to facilitate the separation of the product from the aqueous reaction mixture. The introduction of the benzyloxycarbonyl protecting group (= Z group) is preferably carried out with N-benzyloxycarbonyloxysuccinimide (= Z) in a weakly alkaline range, particularly preferably in solvent water / THF at pH about 8.0 to about 8.5. -OSu). After the reaction is complete, the organic solvent is distilled off, a weakly acidic pH is set, preferably a pH of about 5, and the precipitated compound of formula XXII is filtered off or centrifuged off. If desired, the purity of the compound of formula XXII may be increased prior to the preparation of the amide of formula XXIII, for example by recrystallization from water.
[57] If the enantiomeric purity of the compound of formula XXI or a compound of formula XXII obtainable therefrom by the above method is insufficient, hydrochloric acid is not used and enzymatically and thus enantioselectively in the compound of formula XXI. It is advantageous to split the acetyl group from the amino group. Enzyme deacetalization is carried out analogously to the enzyme deacetylation of (RS) -N-acetylcyclohexylglycine described above, preferably using an acylase "amano" 30000. In a particularly preferred method, the salt of formula XXI isolated following the hydrogenation reaction is initially dissolved in water, and after addition of a base, for example sodium hydroxide, stirred in an alkaline range, for example pH about 10 to about 11, to methyl Hydrolyze the ester. After addition of cobalt (II) chloride as cocatalyst, the acylase is added at a temperature of about 38 to about 40 ° C. at a pH of about 7.8 to about 7.9, for example in an amount of about 5 to about 6 g per kg of compound of formula XXI. Add and stir until the (S) -isomer deacetylates. Subsequently, in order to convert the deacetylated (S) -isomer into the protected benzyloxycarbonylamino compound, preferably a water miscible solvent, for example THF, is added to the reaction mixture as described above and combined with Z-OSu. The reaction is carried out at pH about 8.0 to about 8.5, the organic solvent is distilled off, the mixture is acidified to pH about 5 and the precipitated enantiomeric pure product of formula XXII is isolated.
[58] The conversion of the Z-protected amino acid of Formula (XXII) to the Z-protected amino acid amide of Formula (XXIII) can be carried out using methods conventional to this reaction and known to those skilled in the art. According to a preferred method, the acid of formula (XXII) is activated by conversion to mixed anhydrides using alkyl chloroformates, particularly preferably isobutyl chloroformate. The reaction is preferably carried out of tertiary amines, such as N-ethyldiisopropylamine, in ether such as THF as solvent at a temperature of about -10 to about 0 ° C, preferably about -10 to about -5 ° C. Is carried out in the presence. The ammonia is then incorporated into the mixed anhydride solution at a temperature of about -10 to about 0 ° C, preferably about -10 to about -5 ° C. After conventional workup and crystallization from a solvent such as ethyl acetate, a compound of formula XXIII is obtained in about 87% yield in which the chemical purity and enantiomeric purity in each case are substantially 100%.
[59] Along with the formation of pyridinium salts of formula (XXIV), methylation of pyridine nitrogen atoms in compounds of formula (XXIII) can be achieved by a number of solvents such as alcohols such as isopropanol, amides such as DMF, N, N, N ', N'. Using a number of methylating agents, for example methyl iodide, methyl bromide, methyl chloride or methyl toluene-4-sulfonate, in tetramethylurea), ketones such as acetone or ethers such as THF Preferably it can be performed smoothly at a temperature of about 40 to about 60 ℃. In the reaction of methyl chloride in DMF with a compound of formula XXIII at 45 ° C., for example, a compound of formula XXIV wherein X is Cl is obtained in quantitative yield and purity of about 98.4%. If methylation is to be carried out on a large scale, it is preferable to use methylating agents with lower volatility. For example, since further anion exchange by ion exchange chromatography can be avoided as much as possible, a further aspect regarding the selection of the methylating agent is an anion X contained in the compounds of formulas IV, IX and I and derived from the methylating agent. Properties of these compounds, for example, the solubility of the compounds of formula IV or salts thereof, or the solubility, precipitation properties and physiological fitness of compounds of formula I, which are important in the coupling reaction of compounds of formulas III and IV . Overall, iodide and toluene-4-sulfonate have been found to be particularly preferred, based on their properties, and thus preferred methylating agents are methyl iodide and methyl toluene-4-sulfonate (= methyl tosyl). Rate). In particular, toluene-4-sulfonates are identified by the fact that, in the case of compounds of formula IV or toluene-4-sulfonic acid salts thereof, they can be easily separated, are highly soluble, and have a high peptide coupling rate, In the case of the compounds of I, in particular they are distinguished by surprisingly good precipitation properties, purity and yields. Thus, a particularly preferred methylating agent for the conversion of the compound of formula XXIII to the compound of formula XXIV is methyl toluene-4-sulfonate.
[60] The methylation reaction of the compound of formula (XXIII) with methyl toluene-4-sulfonate is preferably carried out in lower alcohols such as isopropanol as solvents at temperatures of about 40 to about 60 ° C, for example about 50 ° C. Methyl toluene-4-sulfonate is preferably used in slightly excess, for example from about 1 to about 1.2 times the molar amount based on the compound of formula (XXIII). Methylation of the compound of formula XXIII and subsequent removal by hydrogenolysis of the benzyloxycarbonyl protecting group in the compound of formula XXIV may be performed separately. Preferably, methylation and hydrogenolysis are carried out in a one-pot reaction without intermediate separation of the compound of formula XXIV. For this purpose, when a compound of formula XXIV is precipitated from a methylation reaction medium, the compound of formula XXIV is dissolved by, for example, water, and then, under ordinary conditions, for example from about 20 to about 40 ° C., preferably Conventional noble metal catalysts at a temperature of about 20 to about 30 ° C., at a hydrogen pressure of about 1 to about 20 bar, preferably about 1 to about 5 bar, particularly preferably 1 bar, ie at a hydrogen pressure not under hydrogen overpressure. Hydrogenation, for example, in the presence of palladium on carbon. 3-((S) -2-amino-2-carbamoylethyl) -1-methylpyridinium cation (includes the free amino group NH ₂ in the 2-position) and anion X as a counterion, for example tosylate, urine Monocationic salts, i.e. compounds of formula (IV), including odides or chlorides can be separated by themselves. Preferably, the resulting pyridinioalaninamide is separated in the form of a salt with acid HX, i.e. in the form of a dicationic salt of formula IX, and for this purpose, the hydrolysis reaction mixture is subjected to about 1 equivalent of acid HX, i.e. tosyl. For rate, mix with about 1 equivalent of toluene-4-sulfonic acid. After the hydrogenation catalyst has been filtered off, the product can be separated by concentration and crystallization of the residue from an alcohol such as, for example, isopropanol.
[61] The invention also relates to compounds of formula IV wherein X ⁻ is an anion or an anion equivalent, in particular a physiologically acceptable anion such as chloride, bromide, iodide or toluene-4-sulfonate, and salts with acid HX (= Cationic salts of formula (IX)) per se, methods for their preparation and those in which one or more of the above steps are carried out, and their use as intermediates, in particular as intermediates of pharmaceutically active compounds, and in formulas XX, XXI, XXII and Provides the compound of XXIV itself.
[62] The following examples are intended to illustrate the invention. However, the present invention also provides a variant of the above and the following embodiments, for example, where the steps are combined in a one-pot process, or conversely, the method is carried out in a number of separate steps, the steps are performed in a different order, or similar reagents or solvents. Is used or a process in which the rain or aftertreatment method is modified.
[63] Example
[64] Example 1: 4- (2-methyl-5-oxooxazole-4-ylidenemethyl) benzonitrile
[65] Acetone (80.0 L) was incorporated into a mixture of 4-formylbenzonitrile (15.0 kg, 114.5 mol), N-acetylglycine (19.2 kg, 162.4 mol) and anhydrous sodium acetate (9.4 kg, 114.5 mol), then stirred Acetic anhydride (35.0 L, 370.5 mol) was mixed. The reaction mixture is stirred at reflux for 1 hour. The resulting pale yellow suspension is cooled to 50 ° C. and ice water (200 L) is added as soon as possible with stirring and cooling. The mixture is stirred at 20 ° C. for an additional hour. To separate the product, the yellow suspension is compressed on a centrifuge and washed with deionized water (75 L), isopropanol (40 L) and methyl tert-butyl ether (75 L). The product is dried at 40 ° C. under reduced pressure. Yield: 18.17 kg (85.7 mol, 75.2% of theory). Melting point: 192-193 ° C .; MS (DC1): m / z = 213 [M + H ⁺ ]; ¹ H-NMR (DMSO-d ₆ ): δ = 2.42 (s, 3H), 7.30 (s, 1H), 7.96 (d, 2H), 8.33 (d, 2H).
[66] Example 2: (R, S) -cyclohexylglycine
[67] Under nitrogen, (R, S) -phenylglycine (10.0 kg, 66.2 mol) is added to water (78.5 L) and hydrochloric acid (30% concentration, 21.5 L) with stirring. Rhodium on carbon (209.6 g, G 101 S / W 5%, wet with water, Degussa AG) is added with stirring under nitrogen. A hydrogen pressure of 18 bar is applied and the mixture is heated to an internal temperature of 100 ° C. and stirred for 72 hours. The mixture is then cooled to an internal temperature of 50 ° C. Take a TLC sample (butanol / glacial acetic acid / water 2/1/1, R _f [henylglycine] = 0.60, R _f [cyclohexylglycine] = 0.68). After completion of the conversion, the catalyst is filtered off at 50 ° C. and the pH of the filtrate is adjusted to pH 4 using aqueous sodium hydroxide solution (concentrated, about 15 L) at 20 ° C. The mixture is stirred for 30 minutes and the precipitated product is filtered off, washed twice with water (35 L each) and dried at 50 ° C. under reduced pressure. Yield: 9.7 kg (93% of theory). Melting point: greater than 300 ° C .; MS (DC1): m / z (%) = 158 ([M ⁺ + H], 100); ¹ H-NMR (200 MHz, trifluoroacetic acid (TFA)): δ = 1.1-1.6 (m, 5H), 1.7-2.1 (m, 5H), 2.1-2.3 (m, 1H), 4.3 (d, J = 4 Hz, 1H), 11.6 (s, 1H); IR (KBr): ν = 2927.7, 1583.9, 1508.8 cm ^-1 .
[68] Example 3: (R, S) -N-acetyl-cyclohexylglycine
[69] At room temperature, (R, S) -cyclohexylglycine (9.41 kg, 61.7 mol) is added to an aqueous sodium hydroxide solution (concentrated, 30.2 L) in water (134 L) with stirring. The mixture is cooled to an internal temperature of 5 to 10 ° C. and acetic anhydride (15.7 L, 17 kg, 166 mol) is metered in at this internal temperature for 2 hours (exothermic reaction). The pH is then checked and, if necessary, the pH is adjusted to 11 or higher using an aqueous sodium hydroxide solution. The mixture is stirred at an internal temperature of 5-10 ° C. for 1 hour. The internal temperature is then raised to about 23 ° C. and stirring continued for an additional 2 hours. Check that the pH is still 11 every hour. After completion of reaction (TLC, ethyl acetate / methanol / glacial acetic acid / water 70/30/5/5, R _f [acetylcyclohexylglycine] = 0.83, R _f [cyclohexylglycine] = 0.55), the mixture was 5 to Cool to an internal temperature of 10 ° C. The pH is adjusted to pH 3 by the slow addition of hydrochloric acid (30% concentration, about 36 L) at an internal temperature of 5-10 ° C. Stirring is continued for an additional 15 minutes, then the mixture is filtered. The resulting solid is washed twice with water (45 L each) and dried at 60 ° C. under reduced pressure. Yield: 11.52 kg (96.7% of theory). Melting point: 195-197 ° C .; MS (DC1): m / z (%) = 200.2 ([M ⁺ + H], 100); ¹ H-NMR (200 MHz, DMSO-d ₆ ): δ = 0.9-1.3 (m, 5H), 1.5-1.8 (m, 6H), 1.86 (s, 3H), 4.1 (dd, J ₁ = 8 Hz, J ₂ = 6 Hz, 1H), 7.96 (d, J = 8 Hz, 1H), 12.47 (s, 1H); IR (KBr): ν = 3339.7, 2929.3, 1699.9, 1615.7, 1563.2 cm ^-1 .
[70] Example 4: (S) -cyclohexylglycine by enzyme deacetylation of (R, S) -N-acetylcyclohexylglycine
[71] At room temperature, (R, S) -N-acetylcyclohexylglycine (7.95 kg, 39.9 mol) is added to aqueous sodium hydroxide solution (3.65 L, 33% concentration) in water (143 L) with stirring. While stirring, the pH is adjusted to pH 7.8 with hydrochloric acid (2N, about 0.8 L). Cobalt (II) chloride hexahydrate (13.8 g, 0.058 mol) is added with stirring. The mixture is then heated to an internal temperature of 38 to 40 ° C. At a constant internal temperature, 30 000 (40 g, 400 ml of water) of acylase "Amano" is added slowly with stirring. The mixture is stirred slowly for 41 hours, during which time (S) -cyclohexylglycine precipitates slowly. Using hydrochloric acid (30% concentration), the pH is carefully adjusted to pH 5.5-6.0. The mixture is cooled to an internal temperature of 2-5 ° C. and stirred for 1 hour. The precipitated (S) -cyclohexylglycine is filtered off, washed with water (about 16 L) and dried at 60 ° C. under reduced pressure. Yield: 2.79 kg (44.5%). Melting point: greater than 300 ° C .; [α] _D 32.1 ° (c = 1, 1N HCl); ee = 99.78% (GC analysis in Chirasil L-Val, followed by derivatization with propanol / HCl and perfluoropropionic anhydride); MS (DC1): m / z (%) 158 ([M ⁺ + H], 100); ¹ H-NMR (200 MHz, TFA): δ = 1.1-1.6 (m, 5H), 1.7-2.1 (m, 5H), 2.1-2.3 (m, 1H), 4.3 (d, J = 4 Hz, 1H), 11.6 (s, 1 H); IR (KBr); ν = 2927.7, 1583.9, 1508.8 cm ⁻¹ .
[72] To recover unreacted (R) -N-acetylcyclohexylglycine, the mother liquor was adjusted to pH 1 with hydrochloric acid (30% concentration, about 4.3 L) at an internal temperature of 2-5 ° C., and 2-5 ° C. Stir for 1 h. The precipitated (R) -N-acetylcyclohexylglycine is filtered off, washed with water (about 16 L) and dried at 60 ° C. under reduced pressure. Yield: 3.76 kg (47.3%). Melting point: 210 to 212 ° C .; [α] _D -23.5 ° (c = 1, methanol); ee = 98.39% (GC analysis on Kiracil L-Val, followed by derivatization with propanol / HCl or methanol / HCl). ¹ H-NMR, MS and IR data are consistent with data of racemic starting material 4.
[73] Example 5: (R, S) -N-acetylcyclohexylglycine by racemization of (R) -N-acetylcyclohexylglycine
[74] Under nitrogen, (R) -N-acetylcyclohexylglycine (10.9 kg, 54.7 mol) is mixed with glacial acetic acid (24.5 L) and acetic anhydride (1.7 L) with stirring. The internal temperature is increased to 115 ° C. and the mixture is stirred at this temperature for 3.5 hours. The internal temperature is then reduced to about 20 ° C. and water (73 L) is added. The pH of the reaction mixture is 2. The mixture is stirred at 0-3 [deg.] C. for 1 hour, the resulting solids are filtered off, washed twice with water (25 l each) and the material is dried at 60 [deg.] C. under reduced pressure. Yield: 7.95 kg (73% of theory) of (R, S) -N-acetylcyclohexylglycine. Melting point: 195-196 ° C .; α _D 0 ° (c = 1, methanol). ¹ H-NMR, MS and IR data are consistent with the data of the product obtained in Example 3. The mother liquor contains another about 2 kg of (R, S) -N-acetylcyclohexylglycine.
[75] Example 6: (S) -cyclohexylglycine by nonracemic hydrogenation of (S) -phenylglycine
[76] Concentrated sulfuric acid solution (97) in deionized water (0.70 L) with (S) -phenylglycine (90 g, 0.53 mol; R-isomer content less than 1%) stirred at 50 ° C. under nitrogen in a hydrogenation apparatus made of enamel or Hastelloy. % Concentration, 60 g). After all phenylglycine has been dissolved (if necessary, additional sulfuric acid (approx. 5 ml) is added), wetted with rhodium on carbon (6.3 g, 5%, water (50% water), Engelhard type) 5% RH Carb Polcere Escat 30M, Engelhard Code 8000) is added. The hydrogenation unit is sealed and inactivated with nitrogen. The mixture is heated to an internal temperature of 80 ° C. and 20 bar of hydrogen is applied. The total hydrogenation time is 5-6 hours and the hydrogen uptake is about 37 liters. After the hydrogen uptake is terminated, the mixture is further hydrogenated at about 20 bar for an extra 30 to 60 minutes. The mixture is then cooled to an internal temperature of 50 ° C. and the catalyst is filtered off at 50 ° C. using a pressure filter. The catalyst is washed with deionized water (0.30 L) and the filtrate is adjusted to pH 4 by addition of concentrated aqueous sodium hydroxide solution (33% concentration, about 90 ml) at 20 ° C. Stirring is continued for 30 minutes, the precipitated product is suction filtered off and washed with deionized water (0.85 L total) until the wash does not contain sulfate ions. The wet product (about 150 g) is dried at 50 ° C. under reduced pressure. Yield: 80-84 g (86-90% of theory) of (S) -cyclohexylglycine. Optical purity: 99.3% ee.
[77] Example 7: (S) -2- [2-acetylamino-3- (4-cyanophenyl) acryloylamino] -2-cyclohexyl acetic acid
[78] (S) -cyclohexylglycine (3.14 kg, 20 mol) in acetone (70 L) is heated with stirring at 35 ° C. Then, while stirring, 1N aqueous sodium hydroxide solution (20 L) is added for 10 minutes. The mixture is heated to 40 ° C. and vigorously stirred with solid 4- (2-methyl-5-oxooxazole-4-ylidenemethyl) benzonitrile (4.66 kg, 22 mol) for 20 minutes at an internal temperature of 40 ° C. Metering is introduced in several fractions. After the addition is complete, the reaction mixture is stirred at an internal temperature of 40 ° C. for 1 hour. The reaction solution is then filtered through a pressure nutsch coated with Seitzfilter K1000 and activated charcoal (1 kg), and the filter residue is washed with 10 liters of acetone. The filtrate is then cooled to 14 ° C. Then, with stirring, 2N hydrochloric acid (about 10 L) is added for 10 minutes until pH 2.3 is reached. Stirring is continued for 15 minutes and the pH is readjusted with 2N HCl. Then, for 20 minutes, the solution is mixed with deionized water (160 L) with stirring, at which time the title compound precipitates. With stirring, the mixture is cooled to 0 ° C. and stirred at this temperature for 1 hour. For separation, the product is pumped onto a centrifuge, washed three times with water (10 L each), rotary dried and dried under reduced pressure at 40 ° C. Yield: 4.21 kg (11.4 mol, 57% of theory). Melting point: 196-198 ° C .; MS (ESI ⁺ ); m / z = 370.2 [M + H ⁺ ]; ¹ H-NMR (200 MHz, DMSO-d ₆ ); δ = 0.98-1.35 (m, 5H), 1.48-1.90 (m, 6H), 1.99 (s, 3H), 4.20 (dd, 1H), 6.98 (s, 1H), 7.72 (d, 2H), 7.88 ( d, 2H), 8.02 (d, 1H), 9.58 (s, 1H), 12.65 (br s, 1H).
[79] Example 8: (S) -2-[(S) -2-acetylamino-3- (4-cyanophenyl) propionylamino] -2-cyclohexyl acetic acid
[80] In the autoclave, (S) -2- [2-acetylamino-3- (4-cyanophenyl) acryloylamino] -2-cyclohexylacetic acid (7.94 kg, 21.5 mol) was initially added to methanol (100.0 L). ) And the autoclave is carefully inactivated with nitrogen. The catalyst solution is prepared as follows: Methanol (3.0 L) is treated in an ultrasonic bath for 15 minutes, during which time argon is incorporated. Subsequently, (+)-BPPM (10.92 g, 19.65 mmol) and [Rh (COD) Cl] ₂ (4.88 g, 9.75 mmol) were added successively, excluding oxygen, and the mixture was added for an additional 30 minutes in an ultrasonic bath. Let it stand. The yellow-orange catalyst solution is then pumped to the autoclave, excluding oxygen.
[81] Approximately 3 bar of hydrogen is applied three times and the autoclave is immediately drained again. The reaction mixture is heated to an internal temperature of 40 ° C., 10 bar of hydrogen is applied, and then the mixture is hydrogenated with stirring at 40 ° C. for 20 hours. The autoclave is then flushed with nitrogen. The hydrogenation solution is then filtered through a Seitz filter. The filtrate is heated to 50 ° C., deionized water (110 L) is added for 30 minutes and stirring is continued at 50 ° C. for 1 hour. The mixture is then cooled to 15 ° C. and stirred at 15 ° C. for 1 hour. The precipitated product is filtered off through a pressurized nutchu filter, washed with deionized water (20 L) and dried at 40 ° C. under reduced pressure. Yield: 7.73 kg (20.81 mol, 96.7% of theory). Melting point: 209 to 211 ° C .; MS (ESI ⁺ ): m / z = 372.2 [M + H ⁺ ]; ¹ H-NMR (DMSO-d ₆ ): δ = 0.95-1.38 (m, 5H), 1.47-1.80 (m, 6H), 1.72 (s, 3H), 3.10 (2x dd, 2H), 4.15 (dd, 1H), 4.70 (m, 1H), 7.47 (d, 2H), 7.65 (d, 2H), 8.08 (d, 1H), 8.12 (d, 1H), 12.60 (br s, 1H).
[82] Example 9: (S) -2-[(S) -2-acetylamino-3- (4-amidinophenyl) propionylamino] -2-cyclohexylacetic acid betaine
[83] While stirring, methanol (20 L) was added to (S) -2-[(S) -2-acetylamino-3- (4-cyanophenyl) propionylamino] -2-cyclohexyl acetic acid (3.77 kg, 10.1 mol) And hydroxylamine hydrochloride (1.06 kg, 15.2 mol). The mixture is stirred for 10 minutes and then sodium bicarbonate (2.52 kg, 30 mol) is added. The reaction mixture is slowly heated (carbon dioxide release) to an internal temperature of 55 ° C. for 1 hour, then stirred at 55 ° C. for 6 hours and at room temperature overnight. Precipitated sodium chloride is removed by suction filtration using a Seitz filter and washed with methanol (4 L). The methanol solution is concentrated to about 10 L using a rotary evaporator at a bath temperature of about 40 ° C. and added dropwise to isopropanol (60 L) with vigorous stirring. This leads to precipitation of the sodium salt of N-hydroxyamidine. To complete the precipitation, the mixture is concentrated to about 50 L volume with vigorous stirring under reduced pressure at about 40 ° C. The stirring is then continued for 1 hour at 15 ° C. and the product is filtered off through a pressurized nutchu. The precipitate is washed with isopropanol (10 L) and dried overnight on a nutchu filter in a nitrogen stream.
[84] The resulting sodium salt of N-hydroxyamidine is then used directly in the subsequent hydrogenation reaction. To this end, glacial acetic acid (26 L) is initially charged into the autoclave and the sodium salt of N-hydroxyamidine (about 6.2 kg, wet crude product from the reaction) is added in portions with stirring. The solution is mixed with a suspension of palladium on carbon (10%, 50% water; 0.40 kg) in glacial acetic acid (1 L). The autoclave is first flushed with nitrogen and then flushed with hydrogen, and then the mixture is hydrogenated at 50 ° C. for 18 hours at 18 bar of hydrogen pressure. The reaction mixture is cooled to room temperature, filtered through a clear layer seats filter covered with activated charcoal under nitrogen and the filter residue is washed with glacial acetic acid (2 L). The filtrate is not distilled off further and crystallization is initiated. Concentrate on a rotary evaporator at a bath temperature of 50 ° C. The mixture is then cooled to about 25 ° C. and ethyl acetate (20 L) is charged into a flask of a rotary evaporator while the mixture is still rotating, where amidine is precipitated as the acetic acid salt. After 0.5 hour of excess stirring time, the precipitate is suction filtered off by a paper filter and thoroughly dried by suction.
[85] The crude amidinium acetate obtained above is incorporated into deionized water (20 L) heated to 40 ° C. with vigorous stirring and the mixture is heated at 80 ° C. until a clear solution is formed. Then, with vigorous stirring, the mixture is cooled to 15 ° C. within 30 minutes, which precipitates the title compound (as betaine). Stirring is continued at 15 ° C. for 1 hour and the precipitated product is filtered off through a pressurized nutchu. The filter cake is washed with ice water (6 L), dried thoroughly in a stream of nitrogen, transferred to a vessel and stirred with 40 L of acetone for 1 hour under reduced pressure at room temperature. The precipitated product is filtered off through a pressurized nutchu, washed with acetone (about 10 L) and dried at 40 ° C. under reduced pressure. Yield: 2.58 kg (6.64 mol, 65.7% of theory) of the title compound. MS (ESI ⁺ ): m / z = 389.3 [M + H ⁺ ]; ¹ H-NMR (methanol-d ₄ ): δ = 0.98-1.38 (m, 5H), 1.58-1.78 (m, 6H), 1.96 (s, 3H), 3.10 (2x dd, 2H), 4.02 (d, 1H), 4.61 (dd, 1H), 7.42 (d, 2H), 7.68 (d, 2H).
[86] Example 10: 2-Methyl-4- [yridin-3-yl- (Z) -methylene] -4H-oxazol-5-one
[87] Under nitrogen, acetone (40.0 L) is added followed by pyridine-3-carbaldehyde (20.0 kg, 186.9 mol) to N-acetylglycine (32.7 kg, 280.0 mol) and sodium acetate (15.3 kg, 186.9 mol). While stirring, acetic anhydride (40.0 L, 429.0 mol) is added. Within 30 minutes, the reaction mixture is heated to reflux and then stirred at reflux for 1.5 hours. This yields a pale brown suspension. The suspension is cooled to 50 ° C. and then methyl tertiary butyl ether (80.0 L) is added. Ice water (less than 2 ° C., 200.0 L) is added as soon as possible (less than 5 minutes) with stirring and cooling, then the mixture is stirred at 5 to 10 ° C. for 1 hour. The beige suspension is incorporated into a centrifuge inactivated with nitrogen. The precipitate is centrifuged, washed with deionized water (80.0 L) and dried at 40 ° C. under reduced pressure. Yield: 24.8 kg (131.9 mol, 70.6% of theory). Melting point: 173 ° C .; MS (DC1): m / z (%) = 189 ([M + H ⁺ ], 100); ¹ H-NMR (200 MHz, DMSO-d ₆ ): δ = 2.40 (s, 3H), 7.28 (s, 1H), 7.53 (dd, 1H), 8.61 (d, 2H), 9.18 (br s, 1H) ; IR (KBr): ν = 1799.9, 1777.4, 898.0 cm ^-1 .
[88] Example 11: 3- (2-acetylamino-2-methoxycarbonylvinyl) pyridinium tetrafluoroborate
[89] Under nitrogen, a 2-methyl-4- [yridin-3-yl- (Z) -methylene] -4H-oxazol-5-one suspension (12.0 kg, 63.83 mol) in methanol (120.0 L) was heated at 60 ° C. do. Triethylamine (0.5 L) is pumped and the apparatus is washed with methanol (0.5 L) (the pH of the sample taken, measured using a glass electrode, was 8.15). Within 30 minutes. The reaction solution is cooled to 30 ° C. Boron tetrafluoride solution (48% concentration in water, 11.8 kg, 64.5 mol) is added for 30 minutes. Within 1 hour, the mixture is cooled to an internal temperature of 10 ° C. and then the suspension is stirred at 10 ° C. for an additional 3 hours (after seeding, if necessary). Methyl tertiary butyl ether (40.0 L) is added and the mixture is stirred at 10 ° C for 1 h. The suspension is incorporated into a centrifuge inactivated with nitrogen, centrifuged and the product is washed with methyl tertiary butyl ether (20.0 L) and dried at 40 ° C. under reduced pressure. Yield: 18.7 kg (60.71 mol, 95.1% of theory). Melting point: 179.4 ° C .; MS (ESI ⁺ ): m / z (%) = 221 ([M + H ⁺ ] of free base, 100); ¹ H-NMR (200 MHz, DMSO-d ₆ ): δ = 2.01 (s, 3H), 3.77 (s, 3H), 7.21 (s, 1H), 7.89 (dd, 1H), 8.48 (d, 1H), 8.76 (d, 1 H), 8.98 (s, 1 H), 9.92 (s, 1 H); IR (KBr): ν = 1726.9, 1670.1, 1091.5 cm ^-1 .
[90] Example 12: (S) -3- (2-acetylamino-2-methoxycarbonylethyl) pyridinium tetrafluoroborate
[91] In the autoclave, 3- (2-acetylamino-2-methoxycarbonylvinyl) pyridinium tetrafluoroborate (10.3 kg, 33.44 mol) is dissolved in methanol (120.0 L). Boron tetrafluoride solution (50% in water, 1.018 kg, 5.8 mol) is added, the autoclave is sealed and carefully inactivated with nitrogen. The catalyst solution is prepared by treating methanol (3.0 L) for 15 minutes in an ultrasonic bath incorporating argon. Methanol degassed in this way was mixed with (+)-phenyl-CAPP (12.5 g, 20.83 mmol) and [Rh (COD) Cl] ₂ (5.0 g, 10.10 mmol), excluding air, and yellow-orange catalyst The solution is sonicated for 30 minutes under argon. The catalyst solution is incorporated into the autoclave while excluding oxygen. Within an hour. Heat the contents of the autoclave to 40 ° C. In each case, about 3 bar of hydrogen is applied three times and the autoclave is immediately drained again. Then 1.5 bar of hydrogen is applied and the mixture is hydrogenated at 50 ° C. with vigorous stirring. After 7 hours, hydrogenation is stopped. HPLC analysis of the sample taken indicated that at this point in time, 99.1% of the title compound was present, GC analysis (30m fused silica capillary chirasyl Val, isothermal 160 ° C, injector 220 ° C, detector (FID) 260 ° C, carrier Gas hydrogen 0.8 bar, t _ret [(R) enantiomer] 12.64 min, t _ret [(S) enantiomer] 13.64 min) indicate that the enantiomeric purity is (S) isomer 85% ee. The autoclave is flushed with nitrogen and the contents of the autoclave are compressed using a nitrogen filter in a vessel through a Seitz filter and the filtrate is stored at + 5 ° C. under nitrogen.
[92] Four additional asymmetric hydrogenation reactions are carried out using the procedure described above (batch size: 8.0 kg (25.97 mmol) to 10.3 kg (33.44 mol); hydrogen pressure: 2 to 10 bar; temperature: 40 ° C .; hydrogenation time : 4 to 6 hours; product content: 98.0 to 99.9% (HPLC); enantiomeric purity of crude product in hydrogenation solution: 62.0 to 84.5% ee (GC) of S isomer).
[93] Five batches of filtrates are combined and concentrated under reduced pressure to a residual volume of 150 L at a jacket temperature of 40 ° C. Isopropanol (200 L) is added and the mixture is concentrated under a jacket temperature of 40 DEG C to a residual volume of 250 L. At least two times, isopropanol (100 l each) is added and the mixture is concentrated to a 250 l residual volume at a jacket temperature of 40 ° C. This crystallizes the title compound. The white suspension is stirred at 10 ° C. under nitrogen for 1 hour. The product is centrifuged off using a centrifuge inactivated with nitrogen and washed with isopropanol (100 L) and methyl tertiary butyl ether (150 L). This gives 45.0 kg (144.7 mol, 90.6% of theory) of (S) -isomer 71% ee (GC). Melting point: 126.2 ° C. (according to DSC); MS (ESI ⁺ ): m / z (%) = 223 ([M + H ⁺ ] of free base, 100); ¹ H-NMR (200 MHz, DMSO-d ₆ ): δ = 1.78 (s, 3H), 3.08 (dd, J = 9.5 and 7 Hz, 1H), 3.29 (dd, J = 9.5 and 4 Hz, 1H), 4.68 ( m, 1H), 8.00 (dd, J = 5.0 and 4.5 Hz, 1H), 8.42 (t or 2d, J = about 6 Hz, 2H), 8.80 (d, J = about 5 Hz, 1H), 8.82 (s, 1H ); IR (KBr): ν = 1740.9, 1654.3 cm ^-1 .
[94] Example 13: (S) -2-benzyloxycarbonylamino-3- (pyridin-3-yl) propionic acid
[95] (S) -3- (2-acetylamino-2-methoxycarbonylethyl) pyridinium tetrafluoroborate solution (71% ee; 6.70 kg, 21.6 mol) in water (88 L) to activated carbon (0.5 kg) Filter through a coated pressurized nutchu. Using a concentrated aqueous sodium hydroxide solution (33% concentration, about 3.0 L), adjust the pH of the filtrate to 10-11, then stir the solution at 20-25 ° C for 2 hours, at which time the pH is concentrated sodium hydroxide It is kept constant using an aqueous solution. TLC (mobile phase: ethyl acetate / methanol / water / acetic acid 70/30/5/5) shows that the methyl ester is fully hydrolyzed to yield carboxylic acid. Adjust the pH to 8.0 with concentrated hydrochloric acid (about 150 ml). Cobalt (II) chloride hexahydrate (11.7 g, 0.049 mol) is added and the reaction mixture is heated to an internal temperature of 40 ° C. and stirred at a constant temperature of 39 ° C. for 1 hour. While stirring very slowly, 30 000 (38.0 g) of acylase "amano" in deionized water (400 ml) is added at 39 ° C., and then the mixture is stirred for 40 hours at constant pH 7.9 and constant temperature 39 ° C. TLC (mobile phase as described above) is approximately 85% carboxylic acid (corresponding to the content of (S) isomer in 3- (2-acetylamino-2-methoxycarbonylethyl) pyridinium tetrafluoroborate used) Confirm deacetylation. The vessel is inactivated with nitrogen, then tetrahydrofuran (22.0 L) is added and the reaction mixture is cooled to an internal temperature of 10 ° C. for 1 hour. Within 45 minutes, a solution of N- (benzyloxycarbonyloxy) succinimide in tetrahydrofuran (23.0 L) (4.63 kg, 18.6 mol) was added, during which the pH was added to a concentrated aqueous sodium hydroxide solution (33% concentration). The addition is continued to maintain 8.0 to 8.5. The mixture is then stirred at 20 ° C. for 1.5 hours. TLC (mobile phase as described above) indicates complete acylation of free amino acids. Ethyl acetate (60 L) is added to the reaction mixture and then vigorously stirred for 15 minutes. After thorough phase separation, the ethyl acetate phase is separated off and discarded. The aqueous phase is adjusted to pH 5.0 with concentrated hydrochloric acid (ca. 3.7 L), seed crystals of the enantiomerically pure title compound are added and the suspension is stirred at 5 ° C. overnight. Under nitrogen, the crystals are filtered off through a pressurized nutchu, washed with deionized water (20 L) and dried under reduced pressure at 48 ° C. Yield: 2.86 kg (9.52 mol, 51.9% of theory) of 100% ee of the title compound (CSP chiralpak AD 250 × 4.6 mm diecel; mobile phase: isopropanol / ethanol / n-hexane 12/4/84 + 0.1% diethyl Amine; t _ret 14.16 min), [α] _D ²⁰ -9.95 ° (c = 1.0, methanol). Melting point: 173 to 174 ° C (by DSC); MS (ESI ⁺ ): m / z (%) = 301 ([M + H ⁺ ], 100); ¹ H-NMR (200 MHz, DMSO-d ₆ ): δ = 2.85 (dd, J = 9.5 and 7.5 Hz, 1H), 3.10 (dd, J = 9.5 and 3.5 Hz, 1H), 4.23 (m, 1H), 4.98 (s, 2H), 7.15-7.40 (m, 6H), 7.82-7.78 (m, 2H), 8.38-8.50 (m, 2H), 12.80 (br s, 1H); IR (KBr): ν = 3369.7, 1707.4, 1504.7, 1046.9, 699.2 cm ^-1 .
[96] Example 14 Benzyl (S)-[1-carbamoyl-2- (pyridin-3-yl) -ethyl] carbamate
[97] A suspension (2.60 kg, 8.65 mol) of (S) -2-benzyloxycarbonylamino-3- (pyridin-3-yl) propionic acid in tetrahydrofuran (60 L) is cooled to -9 ° C. At this temperature, N-ethyldiisopropylamine (1.33 kg, 10.29 mmol) is added for 5 minutes. Then, at -9 ° C, isobutyl chloroformate (1.36 kg, 9.96 mol) is added within 20 minutes, eventually increasing the internal temperature to -6 ° C. After vigorous stirring for 10 minutes, ammonia gas (2.1 kg, about 123 mol) is incorporated into the resulting thin suspension for 3 hours at a constant temperature of -5 to -6 ° C. The reaction is initially strongly exothermic (it may need to be incorporated slowly initially) and subsequently less exothermic. For 30 minutes, the reaction mixture is warmed to 16 ° C., which gives a thick but still stirring crystal slurry. At a jacket temperature of 30 ° C., the solvent is removed under reduced pressure. The white oily residue is suspended in ethyl acetate (125 L). A solution of sodium hydrogen carbonate (3.0 kg) in water (50 L) is added and the mixture is vigorously stirred for 30 minutes, after which all solids are dissolved. The organic phase is separated off, dried over sodium sulfate (1.0 kg), the desiccant is filtered off and the filtrate is concentrated to about 6 liter volume under reduced pressure at a bath temperature of 30 ° C. The resulting precipitate is filtered off with suction, washed with ethyl acetate (1.5 L) and dried under reduced pressure at 30 ° C. Yield: 2.26 kg (7.55 mol, 87.3% of theory). Chemical purity is 99.9% (HPLC: 125 × 4.0 mm RP18 Purospher, 40 ° C., detection 210 nm); Enantiomeric purity was 100% ee (HPLC: 250 × 4.6 mm CSP Chiralpak AD Daicel, 40 ° C .; detection 248 nm; Mobile Phase: n-hexane / isopropanol / ethanol 84/12/4 + 0.1% diethylamine; t _ret [(S) -isomer] 14.93 min). Melting point: 152.8 ° C. (by DSC); MS (ESI ⁺ ): m / z (%): 300 ([M + H ⁺ ], 100); ¹ H-NMR (200 MHz, DMSO-d ₆ ): δ = 2.77 (dd, J = 9.5 and 7.0 Hz, 1H), 3.02 (dd, J = 9.5 and 3.5 Hz, 1H), 4.19 (m, 1H), 4.96 (s, 3H), 7.00-7.40 (m, 7H), 7.40-7.60 (m, 2H), 7.60-7.76 (m, 1H), 8.36-8.53 (m, 2H); IR (KBr): ν = 3306.8, 1674.9, 1537.7, 1424.0, 1271.6, 1251.3 cm ^-1 .
[98] Example 15 3-((S) -2-ammonio-2-carbamoylethyl) -1-methylpyridinium ditosylate
[99] In the autoclave, isopropanol (1.7 L) was converted to benzyl (S)-[1-carbamoyl-2- (pyridin-3-yl) ethyl] carbamate (1.00 kg, 3.33 mol) and methyl toluene-4-sulfonate ( 0.67 kg, 3.6 mol), the stirrer is turned on and the reaction mixture is stirred in a closed autoclave at 50 ° C. and under nitrogen for 5 hours. The reaction mixture is allowed to stand overnight at room temperature to precipitate the methylated N-benzyloxycarbonyl compound as viscous slime. The reaction solution is diluted with deionized water (0.33 L) and then palladium / carbon (10%, 50% water; 50 g) is added. The hydrogenation reaction is carried out at atmospheric pressure by passing through hydrogen (about 10 L / min) with continuous metered addition of a solution of toluene-4-sulfonic acid monohydrate (0.63 kg, 3.33 mol) in deionized water (1.0 L) at 20-25 ° C. do. After the hydrogenation reaction is complete, the autoclave is flushed with nitrogen, the hydrogenation solution is filtered through a Sates filter and washed with deionized water (0.5 L). The filtrate is transferred to a rotary evaporator and concentrated to about 2.5 liters under a steam-jet vacuum at a bath temperature of 40 ° C. Then, with vigorous stirring, isopropanol (10 L) is charged and the mixture is concentrated to about 5 L with stirring under reduced pressure at a bath temperature of 40 ° C. at which time the title compound begins to crystallize. With stirring, the crystal suspension is cooled at 15 ° C. for 0.5 h and the product is suction filtered off through a paper filter, washed with 1 L of isopropanol, thoroughly suction dried and dried. Yield: 1.57 kg (3.0 mol, 90% of theory). Melting point: 219 to 220 ° C; MS (ESI ⁺ ): m / z (%) = 180.1 ([M + H ⁺ ], 100); ¹ H-NMR (DMSO-d ₆ ): δ = 2.30 (s, 3H), 3.10-3.40 (m, 2H), 4.08 (dd, 1H), 4.35 (s, 3H), 7.12 (d, 4H), 7.48 (d, 4H), 7.70 (s, 1H), 7.90 (s, 1H), 8.05-8.22 (m, 4H), 8.42 (m, 1H), 8.95 (m, 1H).
[100] Example 16: 3-{(S) -2-[(S) -2-((S) -2-acetylamino-3- (4-amidiniophenyl) propionylamino) -2-cyclohexylacetyl Amino] -2-carbamoylethyl} -1-methylpyridinium ditosylate
[101] Under nitrogen, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (1.306 kg, 30.0% on Decalite ^R , 2.40 mol) was converted to N, N-dimethylformamide. 3-((S) -2-ammonio-2-carbamoylethyl) -1-methylpyridinium ditosylate (5.43 kg, 10.36 mol) and (S) -2-[(S) in (45.0 L) 2-acetylamino-3- (4-amidinophenyl) propionylamino] -2-cyclohexylacetic acid betaine (4.00 kg, 93.15% pure, water content: 6.85%, 9.591 mol) and added to the suspension Cool to 10 ° C. At this temperature, a solution of dicyclohexylcarbodiimide (2.56 kg, 99% pure water, 12.28 mol) in N, N-dimethylformamide (3.4 L) at a uniform rate was added by pump for 7 hours and then pump And the tube was washed with N, N-dimethylformamide (0.5 L). The mixture is stirred at 10 ° C. for 1 hour and then warmed to room temperature (23.5 ° C.) for an additional 14 hours. The suspension is filtered through a salts layer and washed with a mixture of N, N-dimethylformamide (2.2 L) and toluene (0.2 L). The filtrate is initially pumped into a vessel filled with acetone (1200 L) for 30 minutes and stirred vigorously at 18 ° C. under nitrogen. The mixture is stirred at room temperature for 10 minutes and then the suspension is compressed with nitrogen through a filter cloth made of polypropylene and a pressurized nutchu coated with a seats filter. The residue is washed with acetone (3 × 100 L) and the solid on pressurized nutchuu is dried overnight with nitrogen and then the precipitation of the product from acetone is repeated. To this end, the solid is dissolved in N, N-dimethylformamide (25 L) with stirring, the solution is mixed with toluene (2.5 L) and pumped into a vessel initially charged with acetone (1200 L) for 15 minutes, It is vigorously stirred at 18 ° C. under nitrogen. The suspension is stirred at room temperature for 10 minutes and then compressed using nitrogen through a pressurized nutchu. Wash the residue with acetone (3 x 100 L). The solid is dried thoroughly in a stream of nitrogen and then initially under reduced pressure at 20 ° C. and then under high vacuum at 43 ° C. Yield: 7.83 kg (8.76 mol, 91.3% of theory). Enantiomeric purity was greater than 99% ee (HPLC: CSP chiral AGP 100 × 4.0 mm 5 μm; 40 ° C., 0.7 ml / min aqueous sodium acetate solution (100 mM); t _ret 6.20 min, t _ret [enantiomer] 4.26 Min, t _ret [diastereomer] 4.97 min); [α] _D ²⁵ -6.5 ° (c = 1.0, water). The chemical purity was 97% and the content of diastereomer was 2.4% (HPLC: Super Sper 60 RPselet B 250 × 4.0 mm; 25 ° C .; detection 210 nm; 1.0 ml / min; Mobile Phase A: 950 ml of water + 50 ml Adjust to pH 3 with acetonitrile + 7 ml of orthophosphoric acid, about 8 ml of triethylamine, mobile phase B: 600 ml of water + 400 ml of acetonitrile + 7 ml of orthophosphoric acid, about 8 ml of triethylamine, adjust to pH 3 Elution program: 100% mobile phase A 15 min followed by 50% mobile phase A + 50% mobile phase B linearly for 10 minutes, 50:50 mixture of these mobile phases equally for additional 15 minutes: t _ret [title cation 13.44 min, t _ret [tosylate anion] 26.88 min). MS (FAB, NBA): for m / z (%) = 722 ([M +], 15% of the mono-tosylate), 550 (tosylate-free cation 1 (N- methyl pyridinium amidine) [M ⁺ ], 100%); ¹ H-NMR (500 MHz, DMSO-d ₆ ): δ = 0.80-1.25 (m, 6H), 1.40-1.70 (m, 5H), 1.72 (s, 3H), 2.29 (s, 6H), 2.71 (d , 1H), 2.98-3.07 (m, 3H), 3.18 (dd, 1H), 4.05 (t, 1H), 4.36 (s, 3H), 4.55-4.65 (m, 2H), 7.11 (d, 4H), 7.27 (s, 1H), 7.42 (s, 1H), 7.47 (d, 4H), 7.51 (d, 2H), 7.73 (d, 2H), 7.92 (d, 1H), 8.06 (dd, 1H), 8.14 (d, 1H), 8.21 (d, 1H), 8.40 (d, 1H), 8.88 (m, 4H), 9.25 (s, 2H); ¹³ C-NMR (75.43 MHz, DMSO-d ₆ , { ¹ H} -broadband decoupled): δ = 20.67 (2C), 22.31 (1C), 25.51 (2C), 25.65 (1C), 28.32 (1C) ), 28.89 (1C), 34.21 (1C), 36.95 (1C), 47.79 (1C), 52.19 (1C), 53.30 (1C), 57.67 (1C), 125.36 (4C), 125.80 (1C), 126.82 (1C) ), 127.70 (1C), 128.03 (4C), 129.59 (1C), 137.74 (2C), 138.13 (1C), 146.36 (1C), 144.68 (1C), 145.25 (2C), 145.37 (1C), 145.63 (1C) ), 165.16 (1C), 169.26 (1C), 170.58 (1C), 171.35 (2C); IR (KBr): ν = 3286, 1663, 1184, 1124, 1035, 1011, 683, 569 cm ⁻¹ .

权利要求:
Claims (15)
[1" claim-type="Currently amended] The compound of formula (II) is converted to a compound of formula (III) or a salt thereof with acid HX by catalytic hydrogenation and the conversion of cyano group to an amidino group, and then reacted with a compound of formula (IV) or salt with acid HX thereof. A process for preparing a compound of formula I, comprising obtaining a compound of formula I wherein anion X is a physiologically acceptable anion.

[2" claim-type="Currently amended] The process of claim 1 wherein the hydrogenation reaction is carried out using a chiral rhodium (I) complex as a catalyst.
[3" claim-type="Currently amended] The hydrogenation reaction according to claim 1 or 2, wherein the hydrogenation reaction is carried out as a catalyst of rhodium (I)-(+)-(2R, 4R) -1-tertiary butyloxycarbonyl-4-diphenylphosphino-2- (di The process is carried out using phenylphosphinomethyl) pyrrolidine complex.
[4" claim-type="Currently amended] 4. The hydrolysis of N-hydroxyamidine according to any one of claims 1 to 3, wherein the conversion reaction of the cyano group to an amidino group is reacted with a hydroxylamine or hydroxylammonium salt and the resulting N-hydroxyamidine The method performed by.
[5" claim-type="Currently amended] The process according to claim 1, wherein the reaction of the compound of formula III or a salt thereof with a compound of formula IV or a salt thereof is carried out in the presence of carbodiimide.
[6" claim-type="Currently amended] The reaction according to any one of claims 1 to 5, wherein the reaction of the compound of formula III or a salt thereof with a compound of formula IV or a salt thereof is dicyclohexylcarbodiimide and 3-hydroxy-4-oxo-3,4 A process carried out in the presence of dihydro-1,2,3-benzotriazine.
[7" claim-type="Currently amended] The process according to claim 1, wherein in the reaction of the compounds of formulas III and IV, the compounds of formula IV are used in salt form with acid HX and the compounds of formula III are used as betaines themselves. .
[8" claim-type="Currently amended] The process according to any one of claims 1 to 7, wherein the anion X ⁻ is toluene-4-sulfonate.
[9" claim-type="Currently amended] The compound of formula la, wherein the anion TosO ^- is toluene-4-sulfonate.
Formula Ia

[10" claim-type="Currently amended] Anion TosO ^- toluene-4-sulfo, comprising reacting a compound of Formula III or toluene-4-sulfonic acid salt thereof with a compound of Formula IVa or a toluene-4-sulfonic acid salt thereof to yield a compound of Formula Ia A process for preparing a compound of formula la, which is a nate.

[11" claim-type="Currently amended] The compound of claim 10, wherein the compound of formula IVa is used in the form of a salt with toluene-4-sulfonic acid, and the compound of formula III is used as its own betaine, the reaction of which is dicyclohexylcarbodiimide and 3-hydr Process carried out in the presence of oxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine.
[12" claim-type="Currently amended] Compounds of formula II and salts thereof.
Formula II

[13" claim-type="Currently amended] Compounds of formula VI and salts thereof.
Formula VI

[14" claim-type="Currently amended] Compounds of formula III and salts thereof.
Formula III

[15" claim-type="Currently amended] A salt of the compound of formula (IV) and its acid HX, wherein anion X is a physiologically acceptable anion.
Formula IV

类似技术:

---

公开号 | 公开日 | 专利标题

---

Aceña et al.2014|Asymmetric synthesis of α-amino acids via homologation of Ni | complexes of glycine Schiff bases. Part 3: Michael addition reactions and miscellaneous transformations

---

US4256836A|1981-03-17|Addition compound of dipeptide derivative and amino acid derivative

---

US4914214A|1990-04-03|Process for the industrial synthesis of perindopril

---

EP0260118B1|1991-12-04|Selective amidination of diamines

---

Ibuka et al.1991|A highly stereoselective synthesis of |-alkene dipeptide isosteres via organocyanocopper-Lewis acid mediation reaction

---

JP4540606B2|2010-09-08|Peptide derivatives having β-secretase inhibitory activity

---

KR100694528B1|2007-03-13|A process for the preparation of perindopril, and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds

---

US5198548A|1993-03-30|Process for the preparation of D| and L|-3,3-diphenylalanine and D| and L|-substituted 3,3-diphenylalanines and derivatives thereof

---

KR100607556B1|2006-08-02|NOVEL METHOD FOR SYNTHESIS OF 2S, 3aS, 7aS-1-[S-ALANYL]-OCTAHYDRO-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AND USE FOR SYNTHESIS OF PERINDOPRIL

---

JP4171423B2|2008-10-22|Process for the preparation of high purity perindopril and useful intermediates for synthesis

---

KR910000234B1|1991-01-23|Process for preparing cis,endo-2-azabicyclo|decane-3-carboxylic acil derivatives

---

US7531673B2|2009-05-12|Preparation of amino acid amides

---

DE4004820A1|1991-04-25|Renininhibitors, method for the preparation and their use in medicinal products

---

KR20040064687A|2004-07-19|Process for production of optically active cis-piperidine derivatives

---

WO1996000736A1|1996-01-11|Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase

---

EP0923372A1|1999-06-23|Pyridinone thrombin inhibitors

---

WO1992020705A1|1992-11-26|Peptide mimetic compounds useful as platelet aggregation inhibitors

---

US20030212250A1|2003-11-13|Peptides

---

Yanagisawa et al.1987|Angiotensin-converting enzyme inhibitors. perhydro-1, 4-thiazepin-5-one derivatives

---

AU2001250467B2|2005-02-17|Method for synthesis of N-[|-1-carboxybutyl]-|-alanine esters and use in synthesis of perindopril

---

US7208607B1|2007-04-24|Process for synthesis of perindopril and pharmaceutically acceptable salts thereof

---

AU2003224420B2|2009-08-06|Process for preparation of perindopril and salts thereof

---

WO2006065826A2|2006-06-22|Process to chiral beta amino acid derivatives by asymmetric hydrogenation

---

KR100498869B1|2005-07-04|Novel method for systhesis of n-[|-1-carboxybutyl]-|-alanine esters and use in synthesis of perindopril

---

EP2121605B1|2013-11-20|Process for preparing |-n-[|-3-amino-1-|-2,3-dioxopropyl]-3-[|-2-[[[|amino]-carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide

同族专利:

---

公开号 | 公开日

---

EP1254159B1|2006-05-10|

---

TWI236481B|2005-07-21|

---

MXPA02006762A|2002-10-23|

---

HRP20020631A2|2004-12-31|

---

YU51202A|2005-11-28|

---

CZ20022583A3|2002-10-16|

---

CA2398497C|2011-04-26|

---

KR100758141B1|2007-09-13|

---

HU0301986A2|2003-09-29|

---

ES2262632T3|2006-12-01|

---

JP2003523364A|2003-08-05|

---

RU2250212C2|2005-04-20|

---

NO20023577D0|2002-07-26|

---

EP1254159A2|2002-11-06|

---

SK10842002A3|2003-04-01|

---

CN1176104C|2004-11-17|

---

CA2398497A1|2001-08-02|

---

NZ520427A|2004-02-27|

---

RU2002123046A|2004-01-10|

---

ZA200205990B|2003-04-30|

---

DK1254159T3|2006-09-11|

---

JP4778181B2|2011-09-21|

---

PT1254159E|2006-07-31|

---

AT325810T|2006-06-15|

---

IL150897D0|2003-02-12|

---

HK1051866A1|2005-05-06|

---

US20010031858A1|2001-10-18|

---

EP1254159B9|2006-06-28|

---

IL150897A|2008-08-07|

---

US7084250B2|2006-08-01|

---

PL356801A1|2004-07-12|

---

AU779722B2|2005-02-10|

---

AR027246A1|2003-03-19|

---

CN1396928A|2003-02-12|

---

US20040225109A1|2004-11-11|

---

BR0107804A|2002-10-22|

---

WO2001055175A2|2001-08-02|

---

WO2001055175A3|2002-02-21|

---

NO20023577L|2002-08-28|

---

EE200200410A|2003-12-15|

---

AU4051601A|2001-08-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
2000-01-28|Priority to DE10003586

---

2000-01-28|Priority to DE10003586.8

---

2001-01-18|Application filed by 아벤티스 파마 도이칠란트 게엠베하

---

2001-01-18|Priority to PCT/EP2001/000523

---

2003-03-06|Publication of KR20030019306A

---

2007-09-13|Application granted

---

2007-09-13|Publication of KR100758141B1

优先权:

---

申请号 | 申请日 | 专利标题

---

DE10003586|2000-01-28|

---

DE10003586.8|2000-01-28|

---

PCT/EP2001/000523|WO2001055175A2|2000-01-28|2001-01-18|Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides|